FDA Approves Beti-Cel Gene Therapy for β-Thalassemia (Cell and Gene Therapy Catapult – Regulatory Round-up – August 2022)
The FDA has approved bluebird bio’s gene therapy betibeglogene autotemcel (beti-cel), now marketed as ZYNTEGLO, the first cell-based gene therapy for the treatment of adult and pediatric patients with beta-thalassemia who require regular red blood cell transfusions.
The FDA news release article can be read here.
See all of Catapult’s Regulatory Round-up for August 2022 here.
Published on the 1st of september 2022.
OpenEdition vous propose de citer ce billet de la manière suivante :
adelage (26 octobre 2022). FDA Approves Beti-Cel Gene Therapy for β-Thalassemia (Cell and Gene Therapy Catapult – Regulatory Round-up – August 2022). ELSIBI. Consulté le 11 octobre 2026 à l’adresse https://doi.org/10.58079/o63t
